Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects.

Xin Jiang,Na Wang,Zun-Jian Zhang,Yuan Tian,Yun Chen
DOI: https://doi.org/10.1055/s-0031-1296521
2011-01-01
Abstract:The bioavailability of a new terbinafine (CAS 91161-71-6) preparation was compared with a commercially available original preparation (reference) of the drug in 19 Chinese healthy male volunteers. The study was performed in an open, randomized, single blind two-sequence, two-period crossover design. Under fasting conditions, each subject received a single oral dose of 250 mg terbinafine as a test or reference formulation with a 7-day washout period between the two preparations. The plasma concentrations of terbinafine were analyzed by a sensitive liquid chromatography-ultraviolet spectrometry method. The pharmacokinetic parameters included AUC(0-tau), AUC(0-infinity), C-max, t(1/2), and T-max. The values of AUC(0-1), demonstrated nearly identical bioavailability of terbinafine from the examined formulations. The AUC(0-48) of terbinafine was 5982.85 +/- 2449.17 and 6761.63 +/- 3140.33 ng.h/ml for the test and reference formulation, respectively. The maximum plasma concentration (C-max) of terbinafine was 1656.25 +/- 623.18 ng/ml for the test and 1552.07 +/- 660.35 ng/ml for the reference product, respectively. No statistical differences were observed for C-max and the area under the plasma concentrationtime curve for terbinafine. The 90 % confidence limits calculated for C-max and AUC from zero to infinity (AUC(0-infinity)) of terbinafine were within the bioequivalence range (80%-125% for AUC). This study shows that the test formulation is bioequivalent to the reference formulation of terbinafine.
What problem does this paper attempt to address?